Mark C. Schneyer - 15 Oct 2026 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)

Reporting relationship: EVP, CHIEF FINANCIAL OFFICER
Issuer ticker: ACAD
Reported as of: 15 Oct 2026
Net transaction value: -$69,342
SEC form: 4
Accepted by SEC: 30 Oct 2026, 20:20:49 UTC
Prior SEC filing: 07 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Jennifer J. Rhodes, Attorney-in-Fact

Filing notes and source

Key filing fact

Mark C. Schneyer filed Form 4 for ACADIA PHARMACEUTICALS INC (ACAD) on 30 Oct 2026.

Key facts

This page summarizes Mark C. Schneyer's Form 4 filing for ACADIA PHARMACEUTICALS INC (ACAD).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 30 Oct 2026, 20:20.

Change

Previous filing in this sequence was filed on 07 Aug 2026.
Current net transaction value: -$69,342.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001899977 Primary reporting owner

Schneyer Mark C.

Relationship: EVP, CHIEF FINANCIAL OFFICER
Address: C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO
Signature: /s/ Jennifer J. Rhodes, Attorney-in-Fact
Signature date: 30 Oct 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ACAD transaction

Common Stock

Award

Transaction value
Shares: +6,815
Change %: +10%
Price: $0.000000^*
Shares after: 74,643
Date: 15 Oct 2026
Ownership: Direct
Footnotes: F1

ACAD transaction

Common Stock

Sale

Transaction value: -$69,342
Shares: -3,321
Change %: -4.4%
Price: $20.88
Shares after: 71,322
Date: 30 Oct 2026
Ownership: Direct
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents acquisition of the Issuer's common stock upon vesting of the performance stock units granted to the Reporting Person on May 1, 2023 at incremental 25% of target. Together with the vesting on August 16, 2024 and September 12, 2025, the performance stock units have vested at 100% of target.

Footnote F2

The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of performance stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).